- Glenmark has launched Tiotropium Bromide Dry Powder Inhaler (DPI) under the brand name – Tiogiva® in UK
- Tiogiva® is the bioequivalent version of Boehringer Ingelheim’s Spiriva® Handihaler®
- Tiotropium Bromide DPI is used in the treatment of chronic obstructive pulmonary disease (COPD)
- Glenmark has a strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and UK
- Glenmark is also planning to launch the product across other markets in Western Europe in future
- Tiotropium DPI had a market size of US$ 450 Mn in the EU in the 12 month period ended September 2020
MUMBAI, India, June 15, 2021 /PRNewswire/ — Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, becomes one of the first companies to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name – Tiogiva®, in UK for the treatment of chronic obstructive pulmonary disease (COPD).
COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissue and a narrowing of the airways, making breathing difficult. There are many different types of the condition, although little is known about what causes this variation and the best way to manage the different versions of the disease1.
According to data from IQVIA, Tiotropium DPI had a market size of US$ 450 Mn in the EU in the 12 month period ended September 2020.
Glenmark’s subsidiary, Glenmark Pharmaceuticals Europe Limited had entered into a strategic, exclusive in-licensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and UK in August 2018. Glenmark is planning subsequent launches of the product across markets in Western Europe under the brand name Tiogiva® in Ireland, Sweden, Finland and Norway; Tavulus® in Denmark, Spain and Netherlands; and Tiotropium Glenmark® in Germany.
Tiotropium Bromide DPI is a bioequivalent version of Boehringer Ingelheim’s Spiriva® Handihaler® and is used in the treatment of COPD.
This is the second inhalation product in-licensed by Glenmark for the European market after Stalpex® (Fluticasone/ Salmeterol) dry powder inhaler.
“We are glad to introduce Tiogiva®, one of the first bioequivalent drugs to be launched in Europe for treatment of COPD. Respiratory medicine is a key area of focus for Glenmark and the launch of this product will enable us to improve access to COPD treatment by providing an effective and high quality treatment option to patients in UK and Western Europe,” said Achin Gupta, EVP & Business Head of EMEA-L, Glenmark Pharmaceuticals Ltd.
About Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It ranks among the world’s top 50 Generics and Biosimilars companies (Top 50 Company Rankings, 2020, from Informa’s Generics Bulletin). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index. For more information, visit www.glenmarkpharma.com
The content is by PR NewsWire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.